{
    "clinical_study": {
        "@rank": "9739", 
        "brief_summary": {
            "textblock": "RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the\n      laboratory may help doctors identify and learn more about biomarkers related to cancer.\n\n      PURPOSE: This clinical trial studies prostate-specific antigen (PSA) antibody levels in\n      samples from patients treated for prostate cancer on trial ECOG-E9802."
        }, 
        "brief_title": "PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802", 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      Primary\n\n        -  To evaluate changes in prostate-specific antigen (PSA) antibody levels over time among\n           patients treated on ECOG-E9802.\n\n      Secondary\n\n        -  To characterize the concordance of PSA antibody assessment between the ECOG Immunology\n           Laboratory and the NCI Immunology Laboratory.\n\n      OUTLINE: Previously tested samples are evaluated for changes in PSA antibody levels over\n      time (from baseline to follow-up at 12 and 24 weeks) at the ECOG Immunology Laboratory and\n      the NCI Immunology Laboratory. Results are compared between the laboratories."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Samples collected on ECOG-E9802 (A Phase II Study of PROSTVAC-V\n        (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox/TRICOM with GM-CSF in Patients with PSA\n        Progression after Local Therapy for Prostate Cancer)\n\n        PATIENT CHARACTERISTICS:\n\n          -  Not specified\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  Not specified"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672905", 
            "org_study_id": "CDR0000738979", 
            "secondary_id": "ECOG-E9802T1"
        }, 
        "intervention": {
            "intervention_name": "laboratory biomarker analysis", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "recurrent prostate cancer", 
            "stage I prostate cancer", 
            "stage IIA prostate cancer", 
            "stage IIB prostate cancer", 
            "stage III prostate cancer"
        ], 
        "lastchanged_date": "August 23, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/ECOG-E9802T1"
        }, 
        "official_title": "Evaluation of PSA Antibody on E9802: Confirmation and Concordance", 
        "overall_official": {
            "affiliation": "Rutgers Cancer Institute of New Jersey", 
            "last_name": "Robert S. DiPaola, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PSA antibody levels are compared between baseline and follow-up at 12 weeks, as well as 24 weeks, using Wilcoxon signed-rank test", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672905"
        }, 
        "responsible_party": {
            "name_title": "Robert L. Comis", 
            "organization": "ECOG Group Chair's Office"
        }, 
        "secondary_outcome": {
            "measure": "Concordance of PSA antibody assessment between the ECOG Immunology Laboratory and the NCI Immunology Laboratory; concordance correlation coefficient will be computed", 
            "safety_issue": "No"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Eastern Cooperative Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}